

Prematurely ended - Statement

EudraCT Number: 2009-014300-55

Full title of the study: Phase II study on the combined systemic and intrathecal chemotherapy with methotrexate, ifosfamide and liposomal cytarabine (DepoCyte®) in patients with HER-2/neu-negative breast cancer and leptomeningeal spread.

Sponsor-ID: MTXIFODepocyte

Sponsor: Charité – Universitätsmedizin Berlin

Study Contact: PD Dr. med. Agnieszka Korfel

Date of early termination: 02.03.2012

Statement: On behalf of the sponsor, this is confirm that above trial never recruited a patient.